Pharmaceutical Technology

JUNE 15, 2023

Japan-based Astellas Pharma has entered a partnership with Cullgen to discover and develop multiple targeted protein degraders through the latter’s proprietary uSMITE targeted protein degradation platform, in a deal potentially worth $1.9bn. This method can target enzymes, transcription factors, scaffold proteins and more.

Protein 130

Protein Development Licensing Licensing 130

XTalks

NOVEMBER 29, 2023

In a significant move towards revolutionizing the alternative dairy protein market, cell programming and biosecurity platform Ginkgo Bioworks has joined forces with Vivici BV , an innovative business-to-business (B2B) ingredients startup. This process ensures optimal protein expression and functionality at a commercial scale.

Protein 105

Protein Production Marketing Development 105

Pharmaceutical Technology

APRIL 6, 2023

Biotheryx and Incyte have signed an agreement for identifying and developing targeted protein degraders for historically undruggable oncology targets. Biotheryx will also receive up to $347m in potential future regulatory and commercial milestone payments, along with tiered single-digit royalties on net product sales across the globe.

Protein 130

Protein Development Sales Production 130

Camargo

NOVEMBER 29, 2021

The development of biological products (or biologics) represents a major advancement in modern medicine, enabling the treatment of patients with many illnesses where no other therapeutics were previously available. Definition of Biologic Products. Biologics include a wide range of products , including: Vaccines.

Development 180

Development Protein Production Hormones 180

Pharmaceutical Technology

MARCH 21, 2023

Gilead Sciences has exercised its option to exclusively license the investigational targeted protein degrader development candidate, NX‑0479, from clinical-stage biopharmaceutical company Nurix Therapeutics. GS-6791 is the first development candidate from the previous collaboration between Gilead Sciences and Nurix in 2019.

Protein 130

Protein Licensing Licensing Sales 130

XTalks

MARCH 26, 2025

In 2025, new initial public offerings (IPOs) are emerging across packaged foods, alternative proteins and tech-enabled food solutions, signaling that scientific investment is becoming a key competitive differentiator. Below is a look at recent beverage and food IPOs of 2025. In February 2025, the company raised approximately $1.14

Packaging 105

Packaging Packaging Protein Production 105

Pharmaceutical Technology

APRIL 22, 2024

Develop a stable cell line for high-titer rAAV production with Ultragenyx's patented method involving HDAC inhibitors and AAV rep proteins. Explore the groundbreaking patent now!

Development 130

Development Protein Production 130

Pharmaceutical Technology

MAY 30, 2023

SK Bioscience has received marketing authorisation from the UK’s medicines and healthcare products regulatory agency (MHRA) for its Covid-19 vaccine, SKYCovion. SKYCovion, a protein-based vaccine created in collaboration with GSK’s pandemic adjuvant, is suitable for storage between 2° and 8° Celsius.

Vaccination 298

Vaccination Vaccine Protein Medicine 298

Pharmaceutical Technology

SEPTEMBER 7, 2022

A recombinant replication-deficient adenovirus vectored vaccine, iNCOVACC has a prefusion stabilised spike protein and is claimed to be the first intranasal vaccine globally to obtain primary two-dose schedule approvals. The nasal delivery system was created and developed to be cost-efficient in low- and middle-income countries.

Vaccination 263

Vaccination Vaccine Clinical Trials Clinical Trials 263

Pharmaceutical Technology

JULY 21, 2022

The company received fast-track designation from the US Food and Drug Administration (FDA) for the eltanexor development programme as a single agent to treat relapsed or refractory intermediate, high or very high-risk MDS patients. MDS are a group of diseases characterised by ineffective blood component production.

Clinical Trials 264

Clinical Trials Clinical Trials Protein Production 264

Pharmaceutical Technology

JUNE 29, 2022

For hundreds of years, we have found myriad uses for microbial enzymes in manufacturing – from food, drink, and household products to a range of industrial applications. Developing best-in-class speciality enzymes. What Pharmatech does is translate the customer needs into a desirable product profile.

Drugs 295

Drugs Gene Therapy Production Manufacturing 295

Pharmaceutical Technology

SEPTEMBER 14, 2022

API peptides and proteins-based drugs have gained much attention in the past decade. Victoza, Copaxone, Lupron, Zoladex, Sandostatin, and Somatuline are some of the popularly marketed peptide API therapeutic drugs while more than 600 peptide-based pharmacological leads are being investigated worldwide, across various phases of development.

Protein 100

Protein Marketing Manufacturing Reagent 100

XTalks

JUNE 1, 2023

Univar Solutions , a leading global distributor of ingredients and chemicals, has recently been chosen to distribute ICL’s Rovitaris line of textured plant proteins in North America. The company prides itself on its relentless drive to continually develop and refine products that fill existing gaps in the market.

Protein 98

Protein Production Development Marketing 98

Fierce Pharma

NOVEMBER 8, 2024

With biomanufacturing often a limiting factor for drug developers, Canada’s Future Fields is heralding its bug-based approach to protein production as a potential salve.

Protein 72

Protein Production Manufacturing Development 72

XTalks

JULY 26, 2023

Brevel , an Israeli startup specializing in the conversion of microalgae into alternative proteins, recently secured $18.5 The Tel Aviv-based startup will use the new funding to deliver an alternative protein source that is neutral in taste, highly functional, remarkably sustainable and accessible to the broader food industry.

Protein 97

Protein Production Cosmetics Marketing 97

pharmaphorum

JULY 27, 2022

Pfizer and BioNTech have started a mid-stage trial of a new version of the COVID-19 vaccine based on a version of the spike protein that they hope will offer greater and broader protection against SARS-CoV-2 variants. The post Pfizer takes COVID jab with ‘enhanced’ spike protein into phase 2 appeared first on.

Protein 122

Protein Immune Response Vaccination Vaccine 122

Pharmaceutical Technology

APRIL 21, 2023

In May 2022, they signed a research partnership and exclusive option licence agreement for the development of antibodies to reduce tumour microenvironment-mediated immunosuppression. Astellas will license a suite of single-domain antibody (VHH) libraries from Twist for five years to conduct research and development activities.

Antibody 264

Antibody Licensing Licensing Protein 264

Pharmaceutical Technology

AUGUST 2, 2022

Sosei Heptares , a corporate brand of Sosei Group Corporation, has signed a new drug discovery partnership and option-to-license agreement with AbbVie for discovering, developing and marketing new therapies for neurological ailments. Additionally, AbbVie will make tiered royalty payments based on global product sales to Sosei Heptares.

Development 147

Development Licensing Licensing Branding 147

Pharmaceutical Technology

JULY 6, 2022

A protein-based vaccine, NVX-CoV2373 is made from the genetic sequence of the SARS-CoV-2 virus’ first strain. The latest development comes after the Committee for Medicinal Products for Human Use of the European Medicines Agency granted a positive recommendation in June this year.

Vaccination 264

Vaccination Vaccine Protein Clinical Trials 264

Pharmaceutical Technology

APRIL 28, 2023

Generate Biomedicines has signed a co-development and commercialisation agreement with the University of Texas MD Anderson Cancer Center to expedite the development of new protein therapeutics for oncology using generative AI. TRACTION is a part of the therapeutics discovery division of MD Anderson.

Development 130

Development Clinical Trials Clinical Trials Protein 130

Pharmaceutical Technology

OCTOBER 3, 2022

Indonesia has granted Emergency Use Authorization (EUA) for the patent-free Covid-19 vaccine, IndoVac, developed by the Texas Children’s Hospital Center for Vaccine Development (CVD) and Baylor College of Medicine, US. A recombinant protein-based Covid-19 vaccine, IndoVac received EUA in the country as a primary shot in adult patients.

Vaccination 130

Vaccination Vaccine Development Production 130

Pharmaceutical Technology

JULY 1, 2022

Twist's VHH libraries, used for discovering and developing antibodies for use in immuno-oncology, will be licensed by Ildong for three years for research and development works. . The post Twist and Ildong to develop antibodies for immuno-oncology applications appeared first on Pharmaceutical Technology.

Antibody 147

Antibody Development Licensing Licensing 147

Pharmaceutical Technology

JUNE 24, 2022

The protein-based vaccine is engineered from the genetic sequence of the SARS-CoV-2 virus’ initial strain. Developed utilising Novavax’s recombinant nanoparticle technology to generate antigen obtained from the coronavirus spike (S) protein, the vaccine is also formulated with the company’s saponin-based Matrix-M adjuvant. “As

Vaccination 263

Vaccination Vaccine Clinical Trials Clinical Trials 263

XTalks

DECEMBER 10, 2024

Rilzabrutinib joins a wave of innovative ITP therapies , including thrombopoietin-receptor agonists like eltrombopag and romiplostim, which boost platelet production. Rilzabrutinib works by targeting BTK, a protein involved in immune cell communication.

Trials 104

Trials Protein Clinical Development Drugs 104

Pharmaceutical Technology

MAY 19, 2023

ImmunoForge has expanded its licence agreement with Duke University in North Carolina, US, to jointly improve research and drug development opportunities. ImmunoForge will expedite the development of new drugs based on the elastin-like polypeptide (ELP) platform technology originally developed by Duke’s Professor Ashutosh Chilkoti.

Development 130

Development Drugs Licensing Licensing 130

Pharmaceutical Technology

JUNE 8, 2023

GenScript ProBio has collaborated with the New York Blood Center Enterprises’ business unit, called Comprehensive Cell Solutions (CCS), to accelerate the development and manufacture of cell and gene therapies. The core objective of the collaboration is to make the therapies affordable and accessible to patients.

Gene Therapy 130

Gene Therapy Gene Development Antibody 130

Pharmaceutical Technology

MARCH 10, 2023

On 10 March, the National Health Service Blood and Transplant (NHSBT) opened a new Clinical Biotechnology Centre (CBC) with the aim of improving the UK’s ability to develop and manufacture cell and gene therapies. Personalised medicines will also be developed at the centre.

Gene Therapy 264

Gene Therapy Manufacturing Gene Clinical Trials 264

Pharmaceutical Technology

NOVEMBER 11, 2022

The European Commission (EC) has granted approval for Sanofi and GSK ’s monovalent, recombinant-protein-based, adjuvanted Covid-19 vaccine, VidPrevtyn Beta, as a booster in adults aged 18 years and above. It is indicated as a booster in people of this age group who were earlier inoculated with a Covid-19 vaccine.

Vaccination 246

Vaccination Vaccine Immune Response Protein 246

Pharmaceutical Technology

SEPTEMBER 5, 2022

The National Medical Products Administration of China (NMPA) has approved CanSino Biologics ’ (CanSinoBIO) recombinant Covid-19 vaccine (Adenovirus Type 5 Vector) for inhalation, Convidecia Air, as a booster. This vaccine leverages the same adenovirus vector technological platform as Convidecia, the intramuscular version.

Vaccination 264

Vaccination Vaccine Genetic Engineering Clinical Trials 264

Drug Discovery World podcast

JANUARY 9, 2025

This is the latest episode of the free DDW narrated podcast, titled Where are the global breakthroughs, opportunities and developments in cancer research?, The post Where are the global breakthroughs, opportunities and developments in cancer research? which covers three articles written for DDW Volume 24 Issue 2, Spring 2023 of DDW.

Development 52

Development Research Protein Production 52

Pharmaceutical Technology

DECEMBER 16, 2022

Sosei Heptares and Eli Lilly and Company have signed a partnership for the discovery, development and commercialisation of small molecules that modulate new G protein-coupled receptor (GPCR) targets linked to diabetes and metabolic diseases. Additionally, Sosei Heptares will receive tiered royalty payments on product sales worldwide.

Development 130

Development Gene Therapy Protein Sales 130

Pharmaceutical Technology

SEPTEMBER 2, 2022

Forma focuses on researching, developing and marketing new therapies for patients with sickle cell disease (SCD), rare hematologic diseases and cancers. A group of ailments, haemoglobinopathies is associated with an irregular production or structure of the haemoglobin protein in the red blood cells.

Clinical Trials 264

Clinical Trials Clinical Trials Protein Trials 264

Pharmaceutical Technology

MAY 25, 2023

ElevateBio has raised $401m in a Series D financing round for advancing its technology platforms to expedite the design, production and development of cell and gene therapies. ElevateBio intends to use the funds to advance its genetic medicine current good manufacturing practice (cGMP) and process development business, BaseCamp.

Gene Therapy 243

Gene Therapy Gene Gene Editing Development 243

Pharmaceutical Technology

DECEMBER 6, 2022

Evaxion Biotech and ExpreS 2 ion Biotechnologies have entered a vaccine discovery collaboration agreement to co-develop a new cytomegalovirus (CMV) vaccine candidate. Additionally, this project will be part of the development pipeline of Evaxion under EVX-V1. Evaluations will follow this method in preclinical models of Evaxion.

Vaccination 130

Vaccination Vaccine Development Immune Response 130

Pharmaceutical Technology

NOVEMBER 14, 2022

binding antibody, a cell-surface protein which is greatly expressed in ovarian cancer, as well as the maytansinoid payload DM4. In February, the company signed a licencing agreement under which Eli Lilly and Company obtained exclusive rights to conduct the research, development and marketing of ADCs. The ADC comprises an FR?-binding

Antibody 246

Antibody FDA Approval Clinical Trials Clinical Trials 246

Pharmaceutical Technology

DECEMBER 8, 2022

Under the prior deal, Daiichi Sankyo acquired exclusive rights for the development, manufacturing and commercialisation of Yescarta in Japan. The delivery of the product is anticipated to begin early next year. Directed against a cell membrane protein called CD19, Yescarta uses the immune system of the patient to destroy cancer.

Licensing 305

Licensing Licensing Gene Therapy Gene 305

Pharmaceutical Technology

APRIL 13, 2023

Clinical-stage biopharmaceutical firm Alentis Therapeutics has raised $105m in a Series C financing round for advancing transformational medicines targeting the CLAUDIN-1 protein. ALE.F02 is being developed for the treatment of advanced kidney, lung and liver fibrosis while ALE.C04 is a potential treatment to target CLDN1-positive tumours.

Medicine 130

Medicine Development Antibody Engineer 130